Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Base Study:~  * Patient has Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease and is treated with a statin, with well controlled LDL-C~* Extension Study:~  * Patient has completed the base study including the reversibility period (i.e. 12 or to up to 24 weeks).~ * Patient is on statin therapy ± lipid-modifying therapy since the end of the base study and planning to continue taking a statin throughout the study~Exclusion Criteria:~* History of heart failure, arrhythmias, heart attack, unstable angina, or stroke within 3 months prior to screening, uncontrolled blood pressure, uncontrolled high cholesterol or liver disease.~* History of mental instability, drug/alcohol abuse within the past 5 years~* Pregnant or breast-feeding~* History of cancer within the last 5 years~* HIV positive~* Donated blood products within 8 weeks~* Currently participating or have participated in a study with an investigational compound within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib (Type: EXPERIMENTAL): Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).